[1]World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global report on surveillance and response. Geneva:World Health Organization,2010:18.[2]Davies GR, Nuermberger EL. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb),2008, 88 Suppl 1: S65-S74.[3]黄正明, 胡克章. 肺结核的药物治疗现状与抗结核药的合理应用.医药导报, 2008,27 (3):250-252.[4]沙巍, 肖和平.未来理想的抗结核药物与化学治疗方案. 中国防痨杂志, 2012, 34 (11): 693-695.[5]Arya DS, Ojha SK, Semwal OP, et al. Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs. Indian J Med Res,2008, 128(5): 611-615.[6]Donald PR, Maritz JS, Diacon AH. Pyrazinamide pharmacokinetics and efficacy in adults and children. Tuberculosis (Edinb),2012, 92 (1): 1-8.[7]Ahmad Z, Nuermberger EL, Tasneen R, et al. Comparison of the ‘Denver regimen’ against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother, 2010, 65 (4): 729-734.[8]周晓映, 原淑鸿, 张红漫. 吡嗪酰胺的不良反应概述. 中国药房, 2008, 19 (5): 388-389.[9]黄仕聪,孙强. 抗结核药所致肝损害46例. 医药导报, 2001, 20 (7): 454-454.[10]李秀丽,杨武军. 吡嗪酰胺临床给药方法. 中国厂矿医学, 2009, 22 (2):225-225.[11]严舒俊. 试谈抗结核药物口服剂型的正确用法.中华结核和呼吸杂志,2007,30 (6): 477.[12]朱慧,李芃,陆宇.LC-MS/MS 方法同时检测人血浆中异烟肼、乙胺丁醇和吡嗪酰胺的浓度. 药物分析杂志, 2012, 32 (6): 11-15.[13]Xu J, Jin HX, Zhu H, et al. Oral bioavailability of rifampicin, isoniazid, ethambutol and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. Clin Thera, 2013, 35 (2): 161-168.[14]Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances: insights from the society of infectious diseases pharmacists. Pharmacotherapy, 2009, 29 (12): 1468-1481.[15]Grosset J, Truffot-PernotC, Lacroix C, et al. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother, 1992, 36 (3): 548-551.[16]Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis, 2010, 50 (6): 833-839.[17]Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Antimicrob Agents Chemother, 2006, 50 (11): 3543-3547.[18]朱莉贞,高孟秋,陈巍,等.复治肺结核化疗新方案与原复治方案的临床对照研究.中国防痨杂志,2012, 34 (5): 304-309. |